HomeALCLS • EPA
add
Cellectis SA
Nakaraang pagsara
€3.01
Sakop ng araw
€2.90 - €3.12
Sakop ng taon
€1.01 - €4.84
Market cap
213.95M EUR
Average na Volume
201.22K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 12.21M | -19.51% |
Gastos sa pagpapatakbo | 29.56M | 14.37% |
Net na kita | -26.32M | -544.41% |
Net profit margin | -215.60 | -652.11% |
Kita sa bawat share | -0.24 | -50.00% |
EBITDA | -15.33M | -105.70% |
Aktuwal na % ng binabayarang buwis | 1.58% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 206.38M | -20.72% |
Kabuuang asset | 324.72M | -15.34% |
Kabuuang sagutin | 248.82M | -1.46% |
Kabuuang equity | 75.90M | — |
Natitirang share | 72.59M | — |
Presyo para makapag-book | 2.87 | — |
Return on assets | -12.99% | — |
Return on capital | -24.65% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -26.32M | -544.41% |
Cash mula sa mga operasyon | -10.36M | -21,942.55% |
Cash mula sa pag-invest | 22.45M | 234.75% |
Cash mula sa financing | -4.14M | -241.54% |
Net change in cash | 9.29M | 158.66% |
Malayang cash flow | 132.49M | 24.52% |
Tungkol
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Itinatag
1999
Website
Mga Empleyado
227
